Anterix (ATEX) names new CFO; grants $250K RSUs, Sept 2025

Anterix, Inc. (ATEX) disclosed a Chief Financial Officer transition: Timothy A. Gray resigned as CFO effective September 19, 2025, and the Board appointed Elena Marquez as CFO effective September 22, 2025.

Accepted by SEC EDGAR 09/18/2025 - 07:27 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Anterix, Inc. (ATEX) disclosed a Chief Financial Officer transition: Timothy A. Gray resigned as CFO effective September 19, 2025, and the Board appointed Elena Marquez as CFO effective September 22, 2025. Ms. Marquez, age 39, has served as Vice President of Finance and Controller since September 2021 and previously held senior finance roles at Clinical Genomics and Prudential Financial. In connection with her promotion, she will receive additional restricted stock units with an aggregate grant date fair value of $250,000 vesting in three equal annual installments and will be eligible to participate in the Company’s Executive Severance Plan. The Board designated her as the company’s principal financial officer and principal accounting officer for SEC purposes. The filing notes standard indemnification and states there are no related-party or Item 404 transactions to disclose.

Positive

• Internal promotion of Elena Marquez supports continuity in finance and accounting operations
• Experience and credentials: Ms. Marquez is a CPA with prior controller and reporting roles
• Clear timeline: resignation effective Sept 19, 2025 and appointment effective Sept 22, 2025 reduces transition uncertainty

Negative

• Departure of incumbent CFO Timothy A. Gray creates a leadership change risk effective Sept 19, 2025
• Equity compensation of $250,000 in RSUs increases potential dilution tied to retention
• Eligibility for Executive Severance Plan introduces potential future cash or benefit obligations

Insights

Corporate Governance Specialist

Internal promotion preserves continuity during the CFO transition.

The appointment of Elena Marquez from Vice President of Finance to CFO effective September 22, 2025 signals an internal succession path that can reduce disruption to financial reporting and operations because she already served as Controller since September 2021.

This matters for investors because an internal successor often shortens the learning curve on accounting policies and ongoing projects, and the Board has formally designated her as principal financial and accounting officer under SEC rules.

Compensation & Finance Analyst

Compensation changes are modest and structured for retention.

Ms. Marquez will receive restricted stock units with an aggregate grant date fair value of $250,000, vesting in three equal annual installments, and will be eligible for the Executive Severance Plan.

These elements aim to align incentives and retain the officer; the grant size is disclosed and quantifies near-term dilution pressure tied to equity compensation.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new CFO of Anterix (ATEX)?

The Board appointed Elena Marquez as Chief Financial Officer, effective September 22, 2025.

When did the prior CFO of ATEX resign?

Timothy A. Gray resigned as CFO effective September 19, 2025.

What compensation did Anterix grant the new CFO?

Ms. Marquez will receive restricted stock units with an aggregate grant date fair value of $250,000, vesting in three equal annual installments, and will be eligible for the Executive Severance Plan.

Does the filing disclose any related-party transactions involving the new CFO?

No. The filing states there are no family relationships and no direct or indirect material transactions requiring disclosure under Item 404.

Will Elena Marquez serve as the principal accounting officer for SEC purposes?

Yes. The Board designated Ms. Marquez as the company’s principal financial officer and principal accounting officer effective upon her appointment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FALSE000130449200013044922025-09-182025-09-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 18, 2025

Anterix Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-36827

33-0745043

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

3 Garret Mountain Plaza Suite 401 Woodland Park, NJ						07424
(Address of principal executive offices)						(Zip Code)

(973) 771-0300

Registrant’s telephone number, including area code

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol			Name of Each Exchange on which registered
Common Stock, $0.0001 par value			ATEX			The Nasdaq Stock Market LLC
						(NASDAQ Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Timothy A. Gray, the Chief Financial Officer of Anterix Inc. (the “Company”), has informed the Company of his resignation as Chief Financial Officer of the Company effective September 19, 2025. In connection with Mr. Gray’s resignation, the Board of Directors of the Company has appointed Elena Marquez, who was serving as the Company’s Vice President of Finance and Controller, as the Company’s Chief Financial Officer, effective September 22, 2025. The Board also designated Ms. Marquez as the Company’s principal financial officer and principal accounting officer for purposes of the rules and regulations of the Securities and Exchange Commission, to be effective upon her appointment as Chief Financial Officer.

Ms. Marquez (39), has been the Company’s Vice President of Finance and Controller since September 2021. Prior to joining the Company, Ms. Marquez held accounting and finance leadership positions at Clinical Genomics, a biotech company and distributor of medical diagnostic products, from September 2018 to September 2021, rising to the rank of Global Controller. Prior to that, Ms. Marquez held various financial reporting roles at Prudential Financial from March 2015 to August 2018 and auditor roles at UHY Advisors from January 2012 to March 2015. Ms. Marquez holds both Bachelor of Science and Master of Science degrees in accounting and information systems from Queens College of the City of New York and is a certified public accountant.

In connection with Ms. Marquez’s promotion, effective September 22, 2025 she will be receiving additional compensation and benefits, including:

•additional restricted stock units with an aggregate grant date fair value of $250,000.00 under the Company’s 2023 Stock Plan, with the restricted stock units vesting in three equal annual installments over a three-year period; and

•eligibility to participate in the Company’s Executive Severance Plan

In connection with her appointment, Ms. Marquez will enter into the Company’s standard form of indemnification agreement for its directors and executive officers with the Company.

Except as set forth above, there are no arrangements or understandings between Ms. Marquez and any other persons pursuant to which she was named to this position with the Company. There are no family relationships between Ms. Marquez and any of the Company’s directors or executive officers or any persons nominated or chosen by the Company to be a director or executive officer. Additionally, Ms. Marquez does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 7.01 Regulation FD Disclosure

On September 18, 2025, the Company issued a press release in connection with the Chief Financial Officer transition. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K furnished under this Item 7.01 shall not be deemed “filed” for any purpose, including for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. Furthermore, the information in this Current Report on Form 8-K furnished under this Item 7.01 shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press Release dated September 18, 2025.
104						Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

			Anterix Inc.
Date: September 18, 2025			/s/ Gena L. Ashe
			Gena L. Ashe
			Chief Legal Officer and Corporate Secretary